DNA-PK Inhibitor Platform for Combination Oncology
c7bio has developed a class of potent inhibitors of DNA-PKcs that combine with targeted therapeutics and multiple radiation modalities to unlock new treatment possibilities for cancer patients.
Development Snapshot
Our lead programs are advancing toward IND in combination settings. We are seeking strategic partners for co-development and licensing.
Platform Focus
Target: DNA-PKcs (targeting the NHEJ pathway)
Modality: Small molecule inhibitors
Strategy: For combination with radiotherapy and chemotherapy
Development Focus
Program 1: Molecular Targeted Therapy enhancers
Program 2: Radioligand combinations
Program 3: Hypoxia-activated DNA-PK inhibitors
Program 4: CRISPR enhancers
Pipeline
c7bio's development programs build on using DNA-PK inhibition to enhance efficacy, improve tumor sensitivity and expand combination opportunities in oncology.
1
Targeted Therapy Combinations
Enhancing efficacy of molecularly targeted oncology agents through DNA repair inhibition to increase tumor sensitivity and address resistance mechanisms.
Development Candidate
2
Radioligand Combination Therapy
Augmenting radioligand-induced DNA damage to improve tumor response and support broader application of radioligand oncology strategies
Pre-clinical
3
Hypoxia activated DNA-PK Inhibitors
Pro-drugged DNA-PK inhibitors targeting hypoxic cells within tumours. Optimized for combination with radiation therapy and select chemotherapies
Lead optimization
Why DNA-PK Inhibition
Precision Mechanism
DNA-PK is a key regulator of DNA repair. Inhibition sensitizes cancer cells to existing and emerging therapies.
Broad Applicability
Works synergistically with multiple treatment modalities, creating combination opportunities across oncology.
Science-Driven
Built on robust preclinical and translational research demonstrating clinical potential.
Development Strategy
- • Biomarker-driven clinical development
- • Combination-first regulatory approach
- • Focus on high unmet need oncology indications
- • Designed for integration into existing pharma pipelines
Development Funding
Partnership Opportunities
c7bio is seeking strategic partners for co-development, licensing opportunities for specific combination programs and collaborations in radioligand and targeted therapy integration.
Team / Contacts
A spin-out from the British Columbia Cancer Research Centre in Vancouver.
For partnership discussions, collaborations or licensing inquiries, contact:
• Professor Andrew Minchinton (aim@c7bio.com)
• Alastair Kyle PhD (akyle@c7bio.com)
